Nanoformula Design for Inducing Non‐Apoptotic Cell Death Regulation: A Powerful Booster for Cancer Immunotherapy

Abstract Cancer treatment has witnessed revolutionary advancements marked by the emergence of immunotherapy, specifically immune checkpoint blockade (ICB). However, the inherent low immunogenicity of tumor cells and the intricate immunosuppressive network within the tumor microenvironment (TME) pose significant challenges to the further development of immunotherapy. Nanotechnology has ushered in unprecedented opportunities and vast prospects for tumor immunotherapy. Nevertheless, traditional nano‐formulations often rely on inducing apoptosis to kill cancer cells, which encounters the issue of immune silencing, hindering effective tumor immune activation. The non‐apoptotic modes of regulated cell death (RCD), including pyroptosis, ferroptosis, autophagy, necroptosis, and cuproptosis, have gradually garnered attention. These non‐apoptotic cell death pathways can induce effective immunogenic cell death (ICD), enhancing cancer immunotherapy. This review comprehensively explores advanced nano‐formulation design strategies and their applications in enhancing cancer immunotherapy by promoting non‐apoptotic RCD in recent years. It also discusses the potential advantages of these strategies in inducing tumor‐specific non‐apoptotic RCD. By deeply understanding the significance of non‐apoptotic RCD in synergistic cancer immunotherapy, this article provides valuable insights for developing more advanced nano‐delivery systems that can robustly induce highly immunogenic non‐apoptotic modes, offering novel research and development avenues to address the clinical challenges encountered by immunotherapy represented by ICB.